Portfolio manager comments — Q4 2024
Fund performance was negative during Q4, with several significant holdings declining after individual events. The largest declines were noted in ASML, Novo Nordisk, AstraZeneca and Ashtead Group. In the case of ASML, major customers postponed deliveries of placed orders that will also make 2025 a year of weak growth. Together with export restrictions in China, this has led to a decline in the valuation of the equity. Novo Nordisk fell sharply in conjunction with the publication of clinical trial results that did not meet expectations. We believe that the extent of the decline is not warranted given that further information is required to assess the quality of the study results. AstraZeneca has been weighed down by uncertainty about the CEO of the operations in China and possible consequences for the company where they previously placated authorities with investments in the country. Ashtead Group has recently been affected by a setback after overinvesting in the post-pandemic upswing, which we view as transient in light of the investment program and plans for industrial expansion being launched in the US. The fund also lost ground due to an insufficient exposure to the financial sector outside of Northern Europe.
We can highlight Compass Group and SAP as the strongest contributors during the quarter, which both have shown stable growth that we expect will continue in 2025. The third primary contributor is a new investment, BMW, where we see a potential for higher distributions in the coming years based on a strong balance sheet and decreased investment requirements after the launch of their new product platform.
The fund’s focus for 2025 is a balance between structural growth and defensive holdings, as well as a broadening of the exposure within the financial sector.